Thank you for participating!

Thank you to all who contributed to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. Ultimately, over 1,000 ideas were submitted, with more than 42,000 votes. This remarkable response exceeded expectations and provided a wealth of ideas to draw upon as NHLBI moves forward. Please visit the NHLBI Strategic Visioning page to find out more about the NHLBI Strategic Visioning process.


Welcome to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. The Institute is gathering ideas for the most compelling scientific priorities in the four NHLBI Strategic Goals to address over the next decade.

(@popkin)

Goal 1: Promote Human Health

Evaluation of large-scale regulatory efforts in the US and elsewhere

A number of cities(e.g Berkeley), states and countries (e.g Mexico's SSB tax, Chiles SSB and soon marketing controls and food package front of package label) will go into effect. Rigorous evaluations of the efforts will provide some sense of their potential to effect food purchase and dietary pattern and ultimately cardiometaboiic changes. Serious rigorous independent evaluations are needed to learn if these options--pushed ...more »

Voting

22 net votes
42 up votes
20 down votes
Active
(@dcenter)

Goal 2: Reduce Human Disease

Improve Repair of injured lung

Why can’t we improve outcomes following acute lung injury. A half century of ICU interventions have resulted in only incremental improvements in survival and morbidity following acute lung injury. While we have pursued innumerable strategies for decreasing ventilator associated exacerbation of lung injury, we have failed to identify treatable common or selective pathways from the initial injury that can be targeted post ...more »

Voting

5 net votes
8 up votes
3 down votes
Active
(@nhlbiforumadministrator1)

Goal 2: Reduce Human Disease

US-based Clinical Development of Innovative Medical Devices

Though innovative medical devices are often conceived of and developed in the US, US consumers are frequently the last to benefit. Innovators frequently go to market first in Europe and are now moving toward emerging countries, delaying the medical benefits available to the US population. Can the NHLBI and FDA’s CDRH, working together as sister agencies, develop strategies such as funding opportunities or collaborative ...more »

Voting

4 net votes
19 up votes
15 down votes
Active
(@kevinfiscella)

Goal 2: Reduce Human Disease

Inflammation: what is the role of the blood microbiome?

Blood is not continuously sterile. Data from dental studies, blood donors, and random blood cultures document that "normal" human blood often harbors microbes. Sepsis only occurs when immunological regulatory systems fail. Growing evidence link subclinical, potentially transient bacteremia to cardiovascular and other diseases. Could many of the diseases associated with inflammatory markers represent either continuous ...more »

Voting

15 net votes
25 up votes
10 down votes
Active
(@bmoore)

Goal 2: Reduce Human Disease

Pathobiology of Lung Fibrosis

End organ fibrosis accounts for up to 45% of deaths in developed countries. In particular, lung fibrosis is a devastating disease with poor prognosis. Despite development of two new drugs, their efficacy is still limited, highlighting the need to better understand the pathobiology that accounts for fibrotic disease progression in the presence and absence of acute exacerbation or infectious drivers.

Voting

19 net votes
30 up votes
11 down votes
Active
(@nhlbiforumadministrator)

Goal 1: Promote Human Health

Human normal variation and resilience across lifespan

What is the measureable normal human variation at the -omic, cellular, organ, and system levels within the population and across the lifespan? • What are the range of normal human cellular functions that create resilience at all levels—cells, organs, organ systems? • What inter-organ, tissue, and cellular communications maintain individual health and the health of populations? • How do we understand why individuals with ...more »

Voting

19 net votes
26 up votes
7 down votes
Active
(@hongw0)

Goal 2: Reduce Human Disease

2. Mechanism and target identification for abnormal epigenetic regulation in cardiovascular disease

Abnormal epigenetic modification has been implicated in human disease. Epigenetic therapy using nonspecific inhibitors for histone acetylation and DNA methylation has been proved effective in some cancer. However, because histone acetylation and DNA methylation are essential biochemical modification of life process, globally suppression on these process would have severe adverse effect. Identification of specific mechanism ...more »

Voting

34 net votes
34 up votes
0 down votes
Active
(@skrenrich)

Goal 4: Develop Workforce and Resources

Retaining Young Investigators

To ensure that young investigators remain in the field, the National Institutes of Health should consider strategies for assisting these investigators in making the career and funding move from mentored career development awards and career development awards for independent investigators (K awards) to research awards (including but not limited to R01 awards).

Voting

14 net votes
15 up votes
1 down votes
Active